ERIS Lifesciences Reports Strong Financial Growth and Improved Profitability Metrics in June 2025

ERIS Lifesciences, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently announced its financial results for the quarter ending June 2025. The company has experienced notable developments in its financial metrics, leading to an adjustment in its evaluation score, which has risen to 15 from 12 over the past three months.
The latest financials reveal that ERIS Lifesciences achieved its highest operating profit to interest ratio in five quarters, recorded at 5.68 times, indicating an enhanced capacity to manage interest obligations. Additionally, the Profit After Tax (PAT) reached Rs 117.99 crore, reflecting a significant year-on-year growth of 41.6%. This trend is mirrored in the net sales, which peaked at Rs 773.00 crore, marking the highest figure in the last five quarters.

The company also reported an operating profit of Rs 276.71 crore and an operating profit margin of 35.80%, both representing the best performance in recent quarters. Furthermore, the Profit Before Tax (PBT) reached Rs 158.41 crore, showcasing a year-on-year growth of 39.10%. The earnings per share (EPS) also hit a high of Rs 8.66, indicating increased profitability for shareholders. The debtors turnover ratio improved to 6.28 times, demonstrating the company's efficiency in managing receivables.

For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.